Jeremy K. Hon
- Oncology top 2%
- Lung Cancer Research Studies 10
- Cancer Treatment and Pharmacology 7
- Colorectal Cancer Treatments and Studies 4
- Cancer Diagnosis and Treatment 4
- HER2/EGFR in Cancer Research 3
-
- Lung Cancer Treatments and Mutations 15
- Lung Cancer Diagnosis and Treatment 7
- Aortic Disease and Treatment Approaches 2
- Hematology top 10%
- Biomaterials top 10%
Jeremy K. Hon
27 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Oncology 1.2k
- Orthopedics and Sports Medicine 208
- Pulmonary and Respiratory Medicine 779
- Hematology 140
- Biomaterials 98
Countries citing papers authored by Jeremy K. Hon
This map shows the geographic impact of Jeremy K. Hon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy K. Hon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy K. Hon more than expected).
Fields of papers citing papers by Jeremy K. Hon
This network shows the impact of papers produced by Jeremy K. Hon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy K. Hon. The network helps show where Jeremy K. Hon may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jeremy K. Hon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 57 | |
| 2 | 2013 | 30 | |
| 3 | 2012 | 92 | |
| 4 | 2012 | 4 | |
| 5 | 2011 | 5 | |
| 6 | 2008 | 25 | |
| 7 | 2007 | 6 | |
| 8 | 2004 | 2 | |
| 9 | 2004 | 4 | |
| 10 | 2004 | 3 | |
| 11 | 2002 | 7 | |
| 12 | Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trialsbreakdown → | 2001 | 520 |
| 13 | 2000 | 1 | |
| 14 | Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer. | 2000 | 12 |
| 15 | 2000 | 36 | |
| 16 | 1999 | 35 | |
| 17 | 1999 | 25 | |
| 18 | 1999 | 5 | |
| 19 | 1998 | 37 | |
| 20 | 1997 | 2 |
About Jeremy K. Hon
Jeremy K. Hon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Oral Surgery, having authored 28 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers), Cancer Treatment and Pharmacology (7 papers), Lung Cancer Diagnosis and Treatment (7 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Diagnosis and Treatment (4 papers), HER2/EGFR in Cancer Research (3 papers) and Aortic Disease and Treatment Approaches (2 papers). The work is most often cited by research in Oncology (1.2k citations), Orthopedics and Sports Medicine (208 citations) and Pulmonary and Respiratory Medicine (779 citations). Jeremy K. Hon has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Vera Hirsh, Mark A. Socinski, Isamu Okamoto, Markus F. Renschler, Paul Bhar, Igor Bondarenko, Nina Karaseva, Hui Zhang, Ihor Vynnychenko and J. L. Mesías Iglesias. Their work appears in journals such as Circulation, Journal of Clinical Investigation and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.